49,267
edits
Difference between revisions of "Hepatitis B"
Jump to navigation
Jump to search
→See also
| (2 intermediate revisions by the same user not shown) | |||
| Line 7: | Line 7: | ||
| Micro = lobular inflammation - hepatocyte necrosis, +/-[[ground glass hepatocytes]] | | Micro = lobular inflammation - hepatocyte necrosis, +/-[[ground glass hepatocytes]] | ||
| Subtypes = | | Subtypes = | ||
| LMDDx = [[hepatitis C]], [[autoimmune hepatitis]], [[primary biliary | | LMDDx = [[hepatitis C]], [[autoimmune hepatitis]], [[primary biliary cholangitis]] without [[granulomas]], [[drug-induced liver disease|drug reaction]] | ||
| Stains = [[Shikata stain]] +ve (not sensitive) | | Stains = [[Shikata stain]] +ve (not sensitive) | ||
| IHC = hepatitis B +ve | | IHC = hepatitis B +ve | ||
| Line 28: | Line 28: | ||
| Prognosis = | | Prognosis = | ||
| Other = | | Other = | ||
| ClinDDx = | | ClinDDx = other hepatitides - viral and non-viral | ||
| Tx = | | Tx = prevention through vaccination, medical treatments (pegylated interferon and nucleoside analogues) | ||
}} | }} | ||
'''Hepatitis B''' is a relatively common [[medical liver disease]] caused by the ''hepatitis B virus''. | '''Hepatitis B''' is a relatively common [[medical liver disease]] caused by the ''hepatitis B virus''. | ||
| Line 38: | Line 38: | ||
*Diagnosis is by serology - details of serologic testing are in the ''[[Medical_liver_disease#Hepatitis_B|medical liver disease article]]''. | *Diagnosis is by serology - details of serologic testing are in the ''[[Medical_liver_disease#Hepatitis_B|medical liver disease article]]''. | ||
*A vaccination is available and done routinely in a many jurisdictions.<ref name=pmid21653306>{{Cite journal | last1 = Leuridan | first1 = E. | last2 = Van Damme | first2 = P. | title = Hepatitis B and the need for a booster dose. | journal = Clin Infect Dis | volume = 53 | issue = 1 | pages = 68-75 | month = Jul | year = 2011 | doi = 10.1093/cid/cir270 | PMID = 21653306 }}</ref> | *A vaccination is available and done routinely in a many jurisdictions.<ref name=pmid21653306>{{Cite journal | last1 = Leuridan | first1 = E. | last2 = Van Damme | first2 = P. | title = Hepatitis B and the need for a booster dose. | journal = Clin Infect Dis | volume = 53 | issue = 1 | pages = 68-75 | month = Jul | year = 2011 | doi = 10.1093/cid/cir270 | PMID = 21653306 }}</ref> | ||
*Medical treatments available for chronic infection - nucleoside analogue | *Medical treatments available for chronic infection - pegylated interferon and nucleoside analogue therapies.<ref>{{Cite journal | last1 = Su | first1 = TH. | last2 = Kao | first2 = JH. | title = Unmet Needs in Clinical and Basic Hepatitis B Virus Research. | journal = J Infect Dis | volume = 216 | issue = suppl_8 | pages = S750-S756 | month = Nov | year = 2017 | doi = 10.1093/infdis/jix382 | PMID = 29156048 }}</ref><ref name=pmid28052634>{{Cite journal | last1 = Chen | first1 = GF. | last2 = Wang | first2 = C. | last3 = Lau | first3 = G. | title = Treatment of chronic hepatitis B infection-2017. | journal = Liver Int | volume = 37 Suppl 1 | issue = | pages = 59-66 | month = Jan | year = 2017 | doi = 10.1111/liv.13309 | PMID = 28052634 }}</ref> | ||
===Associated pathology=== | ===Associated pathology=== | ||
| Line 59: | Line 59: | ||
*[[Hepatitis C]]. | *[[Hepatitis C]]. | ||
*[[Autoimmune hepatitis]]. | *[[Autoimmune hepatitis]]. | ||
*[[Primary biliary | *[[Primary biliary cholangitis]] without [[granulomas]]. | ||
*[[Drug-induced liver disease|Drug reaction]]. | *[[Drug-induced liver disease|Drug reaction]]. | ||
**Pseudo-Lafora bodies in patients on disulfiram (anatabuse) can result in [[ground glass hepatocytes]]. | **Pseudo-Lafora bodies in patients on disulfiram (anatabuse) can result in [[ground glass hepatocytes]]. | ||
| Line 110: | Line 110: | ||
==See also== | ==See also== | ||
*[[Medical liver disease]]. | *[[Medical liver disease]]. | ||
*[[Viruses and cancer]]. | |||
==References== | ==References== | ||